Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 40(3); 2019 > Article
Kim, Yun, Lee, Lee, and Kim: A Review on Safety of Herbal Medicines for Doping

Abstract

Objectives

This study aims to review the herbal medicines containing substances banned by World Anti-Doping Agency(WADA), and to consider criteria for the using of herbal medicines.

Methods

Using foreign(Pubmed, Cochrane, Embase, Google Scholar, WANFANG, CiNii) and domestic databases (NDSL, OASIS, RISS), we analyzed the content and pharmacokinetics of the prohibited substances in herbal medicines.

Results

Herbal medicines containing the prohibited substances proposed in Korea, China, and Japan are Ephedrae Herba, Cannabis Semen, Strychni Semen, Strychni Ignatii Semen, Pinelliae Tuber, Rhizoma Pinelliae, Chelidonii Herba, Papaveris Fructus Deseminatus, Liriopis Tuber, Rehmanniae Radix Recens, Cistanchis Herba, Ponciri Fructus Immaturus, Aurantii Fructus Immaturus, Moschus, Testudinis Plastrum, Otariae Testis et Penis, and Hominis Placenta. Of these, when using Ephedrae Herba, Cannabis Semen, Strychni Semen, Moschus, Strychni Ignatii Semen, and Otariae Testis et Penis, caution is needed in relation to the doping test. Other herbal medicines are considered safe for the doping test. In addition, by analyzing data related to higenamine added to the WADA’s prohibited list of doping since 2017, we don’t recommend using Nelumbinis Plumula. And in the case of the other herbal medicines containing higenamine, it is considered that care should be taken in doping test depending on the amount of usage.

Conclusions

As a result of analyzing the herbal medicines which are in prohibited list about doping, we were able to know the criteria and precautions to use when prescribing the herbal medicines. Further research will be needed about common used herbal medicines and the amount of detection depending on extraction and boiling method.

Fig. 1
Structure of synephrine and isomer
The above is the structure of synephrine. The below three structures are the possible isomers of synephrine depending on the position of the phenolic hydroxyl group.
jkm-40-3-139f1.gif
Table 1
Herbal Medicines Prohibited In-competition
Country Agency Prohibited herbal medicine
Korea Korea Anti Doping Agency(KADA)11) A. Herbal medicine containing prohibited substances
  • Ephedrae Herba

  • Cannabis Semen

  • Strychni Semen

  • Strychni Ignatii Semen

B. Herbal medicine that may contain a small amount of prohibited substances
  • Pinelliae Tuber

  • Rhizoma Pinelliae

  • Chelidonii Herba

  • Liriopis Tuber

  • Moschus

  • Rehmanniae Radix Recens

  • Cistanchis Herba

  • Ponciri Fructus Immaturus

  • Aurantii Fructus Immaturus

  • Testudinis Plastrum

C. Drugs manufactured from raw materials that may contain prohibited substances Hominis Placenta
China China Anti-Doping Agency(CHINADA)12) Not specified
China Food & Drug Administration(CFDA)13) Ephedrae Herba, Strychni Semen, Papaveris Fructus Deseminatus, Moschus (Artificial musk)
Japan Japan Anti-Doping Agency(JADA)14) Not specified
Japan Sport Association(JSPO)15) Ephedrae Herba, Strychni Semen
Tokyo Pharmaceutical Association16) Ephedrae Herba, Strychni Semen, Otariae Testis et Penis, Moschus
Table 2
Herbal Medicines Prohibited at All Times
Country Agency Prohibited herbal medicine
Korea Korea Anti Doping Agency(KADA)11) Not specified
China China Anti-Doping Agency(CHINADA)12)
  • Aconiti Lateralis Preparata Radix

  • Aconiti Tuber

  • Linderae Radix

  • Asia Radix

  • Nelumbinis semen

  • Nelumbinis Plumula (Do not prescribe 408 prescriptions containing this herbal medicine)

Japan Japan Anti-Doping Agency(JADA)14)
  • Nelumbinis semen

  • Tinospora crispa

  • Aconiti Lateralis Preparata Radix

  • Caryophylli Flos

  • Asia Radix

  • Nandina domestica

  • Evodiae Fructus (Do not prescribe 24 prescriptions containing this herbal medicine)

Table 3
Pharmacokinetics of Ephedrine, Pseudoephedrine, Methylephedrine
Year Author Doses and administration Clinical specimen E/PE/ ME PK parameter
1976 Pickup et al29) 22mg of E p.o. serum E Cmax: 79.4ng/mL, Tmax: 1.81h, T1/2: 6.75h
11mg of E p.o.(3 times/day, for 2 weeks) serum E Cmax: 87.4ng/mL, Tmax: 1.86h, T1/2: 6.69h
1997 White et al34) 4 capsules of a powdered ma-huang product* (375mg Ephedra sinica each) p.o.(twice/day) serum E Cmax: 81ng/mL., Tmax: 3.9h, mean T1/2: 5.20h
1998 Gurley et al30) 25mg of E p.o. serum E T1/2: 5.37h
2002 Haller et al28) 2 capsules of Metabolift Thermogenic Diet Formula with water at 8 a.m.(10mg of ephedrine) p.o. serum E Cmax: 63.5ng/mL, Tmax: 2.4h, T1/2: 6.06±1.3h
PE Cmax: 24.1ng/mL, Tmax: 2.4h, T1/2: 6.26±1.6h
2004 He et al35) Mahuang tang p.o. serum E Cmax: 248.50±32.97ng/mL, Tmax: 2.025±0.38h, T1/2: 4.230±1.01h
PE Cmax: 78.89±9.69ng/mL, Tmax: 2.019±0.297h, T1/2: 4.335±0.841h
2005 Chan et al31) 0.6 g of the Mahwang TCM preparation (the therapeutic single-dose amounts) p.o. urine E Cmax: 8.2±0.5μg/mL, Tmax: 7.0±4.8h, T1/2: 5.6±1.2h
PE Cmax: 4.1±0.4μg/mL, Tmax: 6.5±4.3h, T1/2: 4.9±0.9h
2006 Tseng et al32) 25mg of E, 30mg of PE, 20mg of ME p.o. urine E Cmax: 26.9±29.2μg/mL, Tmax: 2–6h
PE Cmax: 115.5±143.8μg/mL, Tmax: 2–6h
ME Cmax: 8.3±7.7μg/mL, Tmax: 4–12h
  • - E, PE in urine completely eliminated from the body at approximately 24–48 h and ME completely eliminated in approximately 48h.

2008 Chan et al36)
  1. single dose(2.5g) Kakkon-to§ extract granules p.o.

  2. multiple dose study; single dose (2.5g) Kakkon-to§ extract granules 3 times/day p.o.(for 3 days, to only one subject)

urine E
  1. Cmax: 4.35±1.82μg/mL (eliminated by the 48h after administration)

  2. 39.03μg/mL

  • - Cmax: 5.33±1.47μg/mL, Tmax: 7.8±4.1h, T1/2: 5.2±1.2h

PE Cmax: 2.66±0.94 μg/mL, Tmax: 7.3±3.6h, T1/2: 4.2±0.9 h
2009 Chan et al37)
  1. single dose(2.5g) Sho-seiryu-to|| extract granules p.o.

  2. multiple dose study; single dose(2.5g) Sho-seiryu-to|| extract granules p.o.(3 times/day, for 3 days, to only 1 subject)

urine E
  1. Cmax: 3.9±1.9μg/mL (eliminated by the 48h after administration)

  2. The first urine’s E concentration: 13.73μg/mL (at 3 days after administration)

  • - Cmax: 4.67±2.11μg/mL, Tmax: 4.75h, T1/2: 5.3±1.2h

PE Cmax: 2.40±1.26μg/mL, T1/2: 4.4±1.0h
2009 Strano-Rossi et al39) 60mg of PE p.o. urine PE
  • - 63.6μg/mL

  • - In 2 of 9 subjects, PE is more than 100μg/mL

  • - 160μg/mL

  • - In 4 of 7 subjects, PE is above 100μg/mL

60mg of PE p.o.(twice/day)
60mg of PE p.o.(twice/day, for 5 weeks) above 100μg/mL(maximum concentration is 275μg/mL.).
60mg of PE p.o.(3 times/day) above 100μg/mL.
12mg of sustained-release formulation of E p.o. E
  • - In 2 of 3 subjects, E is above 10μg/mL.

2010 Strano-Rossi et al40) 60mg of PE p.o. saliva PE
  • - 2h after administration, Cmax is 95ng/mL.

  • - 12h after administration, PE was detected at low concentration or not detected.

urine Tmax: 8–24h
  • - Some subjects was above 100μg/mL.

120mg of sustained-release formulation of PE p.o. saliva PE Cmax: 360ng/mL(at 2–4 h after administration
urine Cmax: 105μg/mL, Tmax: 8–24h
2012 Barroso et al41) 60mg of PE p.o.(4 times/day, for 2 days) (radomized, open-label, two-way crossover study) urine PE Cmax: 170.42μg/mL, Tmax: 36h, T1/2: 4.78h
120mg of PE p.o.(twice/day, for 2 days) (radomized, open-label, two-way crossover study) urine PE Cmax: 173.96μg/mL, Tmax: 44h, T1/2: 7.66h
120mg of PE p.o.(twice/day, for 2 days) (open-label, one-way study) urine PE Cmax: 99.52μg/mL, Tmax: 30h, T1/2: 7.43h
2012 Jo38) Multiple dose study; single dose (2.5g) Ojeok-san extract granules 3 times p.o. urine E Cmax: 3.71±1.5μg/mL, T1/2: 4.77±0.95h
  • - After last administration, Tmax is 3.25±1.79h

2016 Kojima et al33) 25mg of Ephedrine Nagai ® (ephedrine hydrochloride 25 mg/ tablet) and dl-methylephedrine urine E Cmax: 10.3–47.3μg/mL, Tmax: 12h
ME Cmax: 5.9–21.3μg/mL, Tmax: 12h
Powder Fuso ®** (dl-methylephedrine hydrochloride 100mg/g) p.o. serum E Cmax: 113.5–186.1ng/mL, Tmax: 2–8h
ME Cmax: 59.6–121.9ng/mL, Tmax: 2–3h

* Solaray, Inc., Ogden, UT,

† Weight loss aid manufactured by Twin Laboratories Inc, Ronkonkoma, NY

‡ First boil E. sinica Stapf 18g for 20 min, with 10 times water, and then boiled with remaining medicine (Cinnamomum cassia Presl 12g, Prunus armeniaca L. var. ansu Maxim. 12g, Glycyrrhiza uralensis Fisch 6g) for 30 min. After that, filter the boiled Mahuang tang.

§ Galgeun-tang,

|| Socheongryong-tang,

¶ Purchased from Nichi-Iko Pharmaceutical Co., Ltd (Toyama, Japan)

** Purchased from Fuso Pharmaceutical Industries, Ltd (Osaka, Japan)

PK: pharmacokinetics, p.o.: per oral, E: ephedrine, PE: pseudoephedrine, ME: methylephedrine, Cmax: the maximum (or peak) concentration that a drug achieves in a specified compartment, Tmax: the time that it takes a drug or other substance to reach the maximum concentration, T1/2: the time required for a quantity to reduce to half its initial value, h: hours

Table 4
Content of Ephedrine, Pseudoephedrine, Methylephedrine in Ephedrae Herba
Year Author Species Analysis method Extraction method E/PE/ ME Content
1994 Tyler46) - - 2g Ephedrae Herba boiled with 240 mL water, for 10min E 7.5-15mg/g
1997 White et al34) E.sinica UPLC 4 capsules of a powdered ma-huang product* (375mg Ephedra sinica each) twice a day p.o. E 19.4mg/g
PE 4.9mg/g
ME 1.2mg/g
2000 Lee et al42) - UPLC 20g of grinded or ungrinded ma-huang was extracted with 200mL water, for 0.5 or 2h. E
  • - When boiling ungrinded ma-huang for 0.5h (2h), the E content was 5.37mg/g (6.23mg/g).

  • - The concentration was higher when boiled for 2h than 0.5h

  • - The concentration was higher ungrinded ma-huang than grinded ma-huang.

2002 Haller et al28) - LC-MS/MS 2 capsules of Metabolift Thermogenic Diet Formula with water at 8a.m.(equivalent to 10mg of ephedrine) p.o. E 17.3mg/g
PE 5.3mg/g
ME 0.5mg/g
2 capsules consisted of a total of 23.7mg ephedrine alkaloids
2005 Chan et al31) E.sinica Stapf HPLC 0.6g of the Mahwang TCM preparation(the therapeutic single-dose amounts) p.o. E 5660.20μg per 0.6g of the Mahwang TCM preparation
PE 2568.17μg per 0.6g of the Mahwang TCM preparation
ME 682.02μg per 0.6g of the Mahwang TCM preparation
2006 Song et al45) - UPLC 5g of ma-huang(A) or processed ma-huang (B) were boiled with 300mL water for 15min, 30min, 1h, and 2h, respectively. E
  • - After 2h boiling, B’s E content was 21.4mg/g and A’s E content was 18.0mg/g.

  • - In a closed state for 1 day, B’s E content was 23.0mg/g and A’s E content was 19.7mg/g.

  • - The E was more extracted in B than A.

  • - The longer the heating time was, and the more E content was measured.

  • - When left in a closed state for 1 day than after boiling immediately, the more E content was measured.

2008 Chan et al36) - HPLC single dose (2.5g) of Kakkon-to§ extract granules E 3437.50μg/g
PE 1549.23μg/g
ME 415.65μg/g
2009 Chan et al37) - HPLC single dose (2.5g) of Sho-seiryu-to|| extract granules E 2984.2μg/g
PE 1353.6μg/g
ME 361.9μg/g
2016 Aghdasi et al48) E.major HPLC - E
  • - E was not detected in the root of ma-huang.

  • - Dry weight E was 1.21-2.112mg/g in the stem of ma-huang.

2016 Seo et al44) E.sinica Stapf LC-MS/MS 5kg of ma-huang tang (1.75kg of ma-huang) was boiled in 50L of water for 2h. E 204.01mg/g
2017 Tong et al47) E.sinica UPLC 100g of ma-huang in 1.2L of water was boiled for 30min, then cooled for 30min. And remove the foam of the ma-huang, then added 1L of water and boiled for 20min. And remove the foam of the ma-huang one more. E 0.14-3.69mg/mL
PE 0.65-2.57mg/mL
2018 Lee et al43) E.sinica Stapf UPLC 2kg of ma-huang tang (0.7kg of ma-huang) was boiled in 20L of water for 2h. And it is stored at room temperature (23±1°C) and refrigerated (4°C). E
  • - Both at room temperature and refrigerated, both were measured that 2.23-2.68mg/g of E was contained.

  • - After 3 months of storage, there was no significant difference in E content.

* Solaray, Inc., Ogden, UT,

† a weight loss aid manufactured by Twin Laboratories Inc, Ronkonkoma, NY

‡ ma-huang in water was boiled, then remove the foam of the ma-huang,

§ Galgeun-tang,

|| Socheongryong-tang

-, not presented in the study

p.o.: per oral, E: ephedrine, PE: pseudoephedrine, ME: methylephedrine, h: hours, E.: Ephedra, UPLC: Ultra Performance Liquid Chromatography, HPLC: High Performance Liquid Chromatography, LC-MS/MS: Liquid Chromatography with tandem Mass Spectrometry

Table 5
Pharmacokinetics of Δ9-tetrahydrocannabinol (THC)
Year Author Doses and administration Clinical specimen PK parameter
1971 Lemberger et al66) THC administered intravenously to chronic marihuana smokers and non-smokers. serum T1/2 : 28h(chronic smokers), 58h(non-smokers)
1985 Ellis et al57) Cannabis abusers(retrospective study) - The average period of excretion was 27.1 days (20ng/mL or less).
2000 Bosy et al51) 2 capsules containing 48.6μg THC p.o. urine Cmax: 5.2ng/mL, Always detect less than 50ng/mL
Oil containing 172.5μg THC p.o. urine Cmax: 1.8ng/mL, Always detect less than 50ng/mL
Oil containing 315.0μg THC p.o. Cmax: 13.9ng/mL, Detected immediately upon ingestion but detected less than 15ng/mL.. Not detected within 24h after stopping ingestion.
Oil containing 540.0μg THC p.o. Cmax: 21.1ng/mL, Detected within 3-4 days after ingesting oil. Not detected within 24h after stopping ingestion.
Oil containing 546.0μg THC p.o. Cmax: 13.1ng/mL, Detected within 3-4 days after ingesting oil. Not detected within 24h after stopping ingestion.
Oil containing 1762.5μg THC p.o. Cmax: 48.7ng/mL, Detected within 1 day after ingesting oil. Not detected within 72h after stopping ingestion.
2007 Kauert et al61) THC as a low dose(18.2±2.8mg) serum Cmax: 47.8±35μg/L, T1/2: 1.5±0.1h, And fell below 1μg/L for 6h.
THC as a high dose(36.5±5.6mg) serum Cmax: 79.1±42.5μg/L, T1/2: 1.4±0.1h, And fell below 1g/L for 6h.
2008 Zuurman et al64) Rising doses of THC (2, 4, 6 and 8mg) using a Volcano® vaporizer serum T1/2: 7.68min
2008 Hunault et al62) 29.3mg of THC serum Cmax: 135.1μg/L, Tmax: 9.5min
49.1mg of THC Cmax: 202.9μg/L, Tmax: 14.1min
69.4mg of THC Cmax: 231.0μg/L, Tmax: 12.3min
2010 Toennes et al60) Cannabis abusers using an average of 33mg THC, for 10min saliva
  • - occasional marijuana user; Cmax: 49.1±24.9μg/mL, Tmax: 0.1h, T1/2: 1.6±0.2h

  • - heavy marijuana user; Cmax: 120.9±78.1μg/mL, Tmax: 0.1h, T1/2: 3.0±1.5h

2010 Hunault et al63) Cannabis cigarettes containing 29.3mg of THC serum Cmax: 99.5ng/mL, Tmax: 14min, T1/2: 150min
Cannabis cigarettes containing 49.1mg of THC Cmax: 125.0ng/mL, Tmax: 14min, T1/2: 150min
Cannabis cigarettes containing 69.4mg of THC Cmax: 175ng/mL, Tmax: 14min, T1/2: 150min
2010 Brenneisen et al59) 70mg of THC serum Cmax: 20.9±16.7ng/mL, Tmax: 5min
urine Cmax : 0.7±0.3ng/mL within 2h after administration
  • - Not detected within 4-12h after administration.

2018 Pacifici et al65) 1g of marijuana(containing of 0.16% THC) saliva
  • - The concentration was in the range of 2.5-21.5 ng/mL for the first 30 min after smoking and gradually decreased.

urine
  • - The concentration of THC-COOH(major metabolites of THC in urine)was 1.8ng/mL.

THC: Δ9-tetrahydrocannabinol, PK: pharmacokinetics, Cmax: the maximum (or peak) concentration that a drug achieves in a specified compartment, Tmax: the time that it takes a drug or other substance to reach the maximum concentration, T1/2: the time required for a quantity to reduce to half its initial value, h: hours

Table 6
Pharmacokinetics of Strychnine
Year Author Doses and administration Clinical specimen PK parameter
1986 Edmunds et al75) - serum T1/2: 10h, Detection of 1.6mg/L strychnine after 4h of inhalation
1997 Palatnick et al74) Ingested half of a 250mL container of 2% strychnine sulfate(2.5g) serum Cmax: 2.1mg/L, Tmax: 3h, T1/2: 15.9h
- Lethal dose was 100-120mg.
2002 Wood et al76) - serum T1/2: 12h
- The initial concentration at 1.5h after ingestion was 4.73mg/L, falling to 0.38mg/L at 74h post ingestion.
2006 Van Eenoo et al78) Over the counter(OTC) drug 10 pills(380μg of strychnine) p.o. urine Cmax: 22.6-176ng/mL
- Strychnine was detected during 24-48h after administration. And 2.2 8.6% of all ingested strychnine was excreted unchanged in urine during the first 12h after administration.
2010 Li et al79) Treated with 2 Gujinwan capsules (160μg of strychnine) urine 58.2ng/mL at 6h, 28.5ng/mL at 12h, 14.1ng/mL at 18h
2011 Kong et al80) Guo’s Ma Qian Decoction(0.4-1.2 g/day of Ma Qian Zi) p.o.(twice/day, for 8 weeks) serum - Strychnine was detected below 10ng in all subjects. And, during administration and even after the 8-week administration period, there was no accumulated strychnine in the blood.

-, not presented in the study

PK: pharmacokinetics, Cmax: the maximum (or peak) concentration that a drug achieves in a specified compartment, Tmax: the time that it takes a drug or other substance to reach the maximum concentration, T1/2: the time required for a quantity to reduce to half its initial value, h: hours

Table 7
Content of Strychnine
Year Author Species Analysis method Extraction method Content(mg/g)
2009 Tang et al82) - - Extraction with chloroform 18.27
Extraction with ethanol 17.57
Extraction with acidic water 16.04
Extraction with water 14.19
2011 Kong et al80) semen strychni HPLC Guo’s Ma Qian Decoction (0.4-1.2g/day of Ma Qian Zi) 9.55 (in 0.4g), 9.95 (in 0.6g), 9.78 (in 0.8g), 10.03 (in 1.0g), 9.31 (in 1.2g)
2012 Xu et al81) - HPLC Analyze Strychnos nux-vomica powders 6 times 12.1065
2015 Hu83) - - Raw Ma Qian Zi 18.24
Ma Qian Zi heated with sand* 16.25
Ma Qian Zi processed with Glycyrrhizae oil 9.27
Ma Qian Zi with 5% acetic acid 4.67
Deep frying Ma Qian Zi§ 10.25
Ma Qian Zi with vinegar|| 10.57

-, not presented in the study

* 砂烫, First, warm the sand with fire, then fill in the Ma Qian Zi. and fry until brown or dark brown, filter the sand and cool.

† 甘草制, After diluting the Glycyrrhizae oil 10 times, add the Ma Qian Zi and boil. After 4h boiling, remove the Glycyrrhizae oil, and dry at 60°C.

‡. 醋泡, Dipping the Ma Qian Zi in water for 2 days, running for 0.5 days, dividing into 1.5 mL. And dipping in 5% acetic acid for 5 days, washing with water, and drying at 60°C after 3 days.

§ 油炸, Put the Ma Qian Zi into the boiling pots of oil, and when it is yellow, take it out and cool it down.

|| 醋炙, Mix Ma Qian Zi and vinegar evenly, and when the vinegar disappears, cool down.

HPLC: High Performance Liquid Chromatography, p.o.: per oral

Table 8
Content of Ephedrine in Pinelliae Tuber, Rhizoma Pinelliae
Year Author Herbal medicine Content(mg/g)
2005 Li et al86) Anhuisheng-bozhou*’s Pinelliae Tuber, Rhizoma Pinelliae 0.007
Hubeisheng-daye’s Pinelliae Tuber, Rhizoma Pinelliae 0.001
Hubeisheng-enshi’s Pinelliae Tuber, Rhizoma Pinelliae 0.001
Guiyang§’s Pinelliae Tuber, Rhizoma Pinelliae 0.003
Hubeisheng-Huangshi||’s Pinelliae Tuber, Rhizoma Pinelliae 0.004
Guizhou’s Pinelliae Tuber, Rhizoma Pinelliae 0.001
2007 Xu et al84) Analyze Rhizoma Pinelliae, Rhizoma Typhonii Flagelliformis and their processed products 5 times 0.0017
2008 Qi et al85) Analyze Pinelliae Tuber granules 6 times 0.0287
2009 Zhu et al87) Wild Pinelliae Tuber and Rhizoma Pinelliae 0.0055
Cultivated Pinelliae Tuber, Rhizoma Pinelliae 0.0039

* 安徽亳州,

† 湖北大冶,

‡ 湖北恩施,

§ 贵阳

|| 湖北黄石,

¶ 贵州

Table 9
Pharmacokinetics of Synephrine
Year Author Doses and administration Clinical specimen PK parameter
2013 Medana et al101) 15mg of synephrine p.o. urine Cmax: 14.3μg/L (at 3h after administration)
2018 Shara et al102) A single oral dose of 49mg p-synephrine in bitter orange extract(for 15 days) serum - 1 week after administration: 2.54±1.54ng/mL
- 2 weeks after administration: 2.69±1.52ng/mL

PK: pharmacokinetics, p.o.: per oral, Cmax: the maximum (or peak) concentration that a drug achieves in a specified compartment, h: hours

Table 10
Content of Synephrine
Year Author Herbal medicine Content
2003 Ke et al103) Analyze Citrus Auarntium L. 3 times 1.1146mg/g, 1.129mg/g, 1.9553mg/g
2006 Luo et al104) Analyze Citrus Auarntium L. 5 times 8.3mg/g
2006 Lu et al105) Analyze Citrus Auarntium L. 6 times 8.4mg/g
2006 Zhao et al106) Analyze Aurantii Fructus Immaturus 4.5mg/g
Analyze Aurantii Fructus 1.3mg/g
2007 Nelson et al107) Analyze Citrus aurantium fruit 8.85mg/g (dry weight of synephrine)
Analyze Citrus aurantium extract 71.5mg/g (dry weight of synephrine)
2014 Shawky108) Analyze Citrus aurantium fruit(bitter orange) 2.53mg/g
2018 Tanaka et al109) In citrus fruits(mikan, orange, bitter orange, and ponkan samples) <(R)-synephrine>
exocarp(0.264±0.0087mg/g), mesocarp(0.174±0.0096mg/g), endocarp(0.094±0.0096mg/g), sarcocarp(0.021±0.0103mg/g)
<(S)-synephrine>
exocarp < 0.0025mg/g, the other parts < 0.0008mg/g

L.: Linne

Table 11
Steroid Content in Musk (μg/g)
Steroid 1* 2* 3*
An 303 152 321
Etio 3164 419 1673
5α-diol 273 24 16
5β-diol 269 26 399
DHEA 88 41 46
EpiA 180 61 188
T 28 32 97
ET 36 29 76
4-AD 273 80 2968
DHT <10 <10 <10
5α-3β,17α-diol 838 97 1504
5α-3β,17β-diol 14 <0.5 25
5α-dione 119 73 580
E <24 - <24
Ediol - - -
Preg <24 <24 <24
Prog <21 - <21
Etriol - - -
17OHPreg - - -
Chol 1609 780 2571

* musk sample number. 1, 2 is Moschus sp. and 3 is Moschus berezovskii.

† Steroids prohibited according to the WADA Prohibited List 201810).

-, not detected.

An: androsterone, Etio: etiocholanolone, 5α-diol: 5α-androstane-3 α,17β-diol, 5β-diol: 5β-androstane-3α,17β-diol, DHEA: dehydroepiandrosterone, EpiA: epiandrosterone, T: testosterone, ET: epitestosterone, 4-AD: 4-androstene- 3,17-dione, DHT: 5α-dihydrotestosterone, 5α-3 β,17α-diol: 5α-androstane-3β,17α-diol, 5α-3β,17β-diol: 5α -androstane-3β,17β-diol, 5α-dione: 5α-androstane-3,17-dione, E: estrone, Ediol: estradiol, Preg: pregnenolone, Prog: progesterone, Etriol: estriol, 17OHPreg: 17-OH-pregnenolone, Chol: cholesterol

Table 12
Higenamine Content of Herbal Medicine according to the Method of Analysis
Year Author Herbal medicine Analysis method Content(μg/g)
2011 Tian134) Nelumbinis Plumula HPLC 920
Asiasarum heterotropoides F. Maekawa var. mandshuricum F. Maekawa 84
Aconiti Lateralis Preparata Radix 22
2012 Tian et al135) Nelumbinis Plumula HPLC 940
2018 Yang et al136) Phellodendri Cortex LC-MS/MS 8.216
Zanthoxylum bungeanum Maximowicz 5.010
Asia Radix 8.66
Kochiae Fructus 4.66
Caryophylli Flos, Phlomis umbrosa Turcz., Corydalis Tuber, Carthami Flos, Draconis Sanguis, Paeonia lactiflora Pall., Nelumbo nucifera, Aucklandiae Radix, Cinnamomi Cortex, Cnidium officinale Makino, Angelicae Pubescentis Radix, Angelicae Gigantis Radix, Osterici Radix, Rhei Rhizoma, Vladimiriae Radix, Myrrha, Sargendoxae Caulis, Angelicae Dahuricae Radix -

-, not extracted

HPLC: High Performance Liquid Chromatography, LC-MS/MS: Liquid Chromatography with tandem Mass Spectrometry

Table 13
Content of Higenamine of Herbal Medicine according to the Extraction Method (μg/g)
Herbal medicine Extraction method

In pressure Non-pressure

Water extraction (Water 100%) Alcohol extraction (Water: Alcohol=7:3) Water extraction (Water 100%) Alcohol extraction (Water: Alcohol=7:3)
Processed Aconiti Lateralis Preparata Radix 0.211 0.294 0.108 0.278
Asia Radix 5.168 3.841 3.114 6.415
Processed Evodiae Fructus 2.835 2.668 1.692 2.724
Linderae Radix 3.488 5.318 2.407 3.918
Nelumbinis Semen 1.074 1.407 1.117 1.09
Processed Aconiti Tuber 0.163 0.225 0.112 0.1305
Processed Aconiti Ciliare Tuber 7.002 9.322 5.476 5.38

참고문헌

1. Verroken M. Drug use and abuse in sport. Baillieres Best Pract Res Clin Endocrinal Metab. 2000; 14:1–23.
crossref pmid

2. Kim JH. Sports-moral and ethical aspects. Seoul: Rainbowbooks;2015. p. 97–9.


3. Lee HS. Sports sociology. Seoul: Sungshin press;2004:p. 301


4. Kim JR. A counter-strategy of Korea for anti-doping policy in world sports [dissertation]. Seoul: Hansung University;2002.


5. Judkins C, Prock P. Supplements and inadvertent doping - how big is the risk to athletes. Med Sport Sci. 2012; 59:143–52.
crossref pmid

6. Kim JK, Chun YS, Kang SK, Cho HC. The use of herbal/traditional products supplementation and doping tests in elite athletes. Korean Journal of Sport Science. 2009; 20:4. 734–42.
crossref

7. Yun SJ, Je JJ, Lee H, Kim YJ, Lee HS. Anti-dopping of herbal medicine in 2015. J Sports Korean Med. 2015; 15:1. 1–9.


8. Kim JK, Kang SK, Jung HS, Chun YS, Trilk J, Jung SH. Dietary supplementation patterns of Korean olympic athletes participating in the Beijing 2008 summer olympic games. Int J Sport Nutr Exerc Metab. 2011; Apr. 21:2. 166–74.
crossref

9. Yun SJ. Anti-doping of herbal medicine in 2018. The Korean Medicine Times. 2018; Jul. 2. 2171:23(col. 1)


10. World anti-doping agency(WADA) [Internet]. Montreal(Quebec): WADA;2018. c2018[cited 2018 Oct 3]. Available from: https://www.wada-ama.org/


11. Korea anti doping agent [Internet]. Seoul: KOREA ANTI-DOPING AGENCY;c2014. [cited 2018 Oct 3]. Available from: https://www.kada-ad.or.kr/


12. China anti-doping agency [Internet]. Beijing: CHINADA;c2015–2016. [cited 2018 Oct 3]. Available from: http://www.chinada.cn/


13. CFDA [Internet]. Beijing: CFDA;[cited 2018 Oct 3]. Available from: http://eng.sfda.gov.cn/WS03/CL0755/


14. Japan anti-doping agency(JADA) [Internet]. Tokyo: JAPAN Anti-Doping Agency;[cited 2018 Oct 3]. Available from: https://www.playtruejapan.org/


15. JSPO [Internet]. Tokyo: Japan Sport Association;[cited 2018 Oct 3]. Available from: https://www.japan-sports.or.jp/


16. Tokyo pharmaceutical association [Internet]. Tokyo: TOKYO PHARMACEUTICAL ASOCIATION;[cited 2018 Oct 3]. Available from: http://www.toyaku.or.jp/index.html


17. UEFA [Internet]. Switzerland: UEFA;c1998–2018. UEFA competitions cases: July-december 20162017. Apr. 19. [cited 2018 Nov 24]; [about 104 p.]. Available from: https://www.uefa.com/MultimediaFiles/Download/OfficialDocument/uefaorg/UEFACompDisCases/02/45/96/63/2459663_DOWNLOAD.pdf


18. Ministry of Food and Drug Safety [Internet]. Cheongju: Ministry of Food and Drug Safety; The Korean pharmacopoeia;11th edition. 2018. Oct. 14. [cited 2018 Nov 24]; [about 2554 p.]. Available from: http://drug.mfds.go.kr/html/menuLinkBody.jsp?p_menuId=0514


19. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: A comprehensive review. Prog Cardiovasc Dis. 2005; Jan–Feb. 47:4. 217–25.
crossref pmid

20. Herbal Pharmacology textbook compilation committee. Herbal pharmacology. 4th ed. Seoul: Shinilbooks;2015. p. 202–7. p. 260–5. p. 348–64. p. 365–9. p. 733–5. p. 799–803. p. 877–80. p. 934–7.


21. Kim HC. Herbal medicine pharmacology. Seoul: Jipmoon;2001. p. 63–6. p. 180


22. Rice J, Proctor K, Lopardo L, Evans S, Kasprzyk-Hordern B. Stereochemistry of ephedrine and its environmental significance: Exposure and effects directed approach. J Hazard Mater. 2018; Apr. 15. 348:39–46.
crossref pmid

23. Soni MG, Carabin IG, Griffiths JC, Burdock GA. Safety of ephedra: Lessons learned. Toxicol Lett. 2004; Apr. 15. 150:1. 97–110.
crossref pmid

24. Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: An analysis of food and drug administration reports of adverse events. Am J Psychiatry. 2005; Jan. 162:1. 189–91.
crossref pmid

25. Song YK, Lim HH. Clinical application of ma huang in the obesity treatment. Journal of Society of Korean Medicine for Obesity Research. 2007; 7:1. 1–7.


26. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord. 1993; Feb. 17:Suppl 1. S41–3.
pmid

27. Wilkinson GR, Beckett AH. Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. J Pharm Sci. 1968; Nov. 57:11. 1933–8.
crossref pmid

28. Haller CA, Jacob P, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther. 2002; Jun. 71:6. 421–32.
crossref pmid

29. Pickup ME, May CS, Ssendagire R, Paterson JW. The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. Br J Clin Pharmacol. 1976; Feb. 3:1. 123–34.
crossref pmid pmc

30. Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang) . Ther Drug Monit. 1998; Aug. 20:4. 439–45.
crossref pmid

31. Chan KH, Pan RN, Hsu MC. Simultaneous quantification of six ephedrines in a Mahwang preparation and in urine by high–performance liquid chromatography. Biomed Chromatogr. 2005; Jun. 19:5. 337–42.
crossref

32. Tseng YL, Shieh MH, Kuo FH. Metabolites of ephedrines in human urine after administration of a single therapeutic dose. Forensic Sci Int. 2006; Mar. 10. 157:2–3. 149–55.
crossref pmid

33. Kojima A, Nishitani Y, Sato M, Kageyama S, Dohi M, Okano M. Comparison of urine analysis and dried blood spot analysis for the detection of ephedrine and methylephedrine in doping control. Drug Test Anal. 2016; Feb. 8:2. 189–98.
crossref pmid

34. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardiovascular effects of ma–huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997; Feb. 37:2. 116–22.
crossref

35. He F, Luo J, Chen F, Yu L. Human pharmacokinetics of ephedrine and pseudoephedrine in Mahuang Tang by GC-MS. Traditional Chinese Drug Research and Clinical Pharmacology. 2004; Sep. 15:5. 336–8. 347


36. Chan KH, Pan RN, Hsu MC, Hsu KF. Urinary elimination of ephedrines following administration of the traditional Chinese medicine preparation Kakkon-to. J Anal Toxicol. 2008; Nov–Dec. 32:9. 763–7.
crossref pmid

37. Chan KH, Hsu MC, Chen FA, Hsu KF. Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. J Anal Toxicol. 2009; Apr. 33:3. 162–6.
crossref pmid

38. Jo YK. The study on anti-doping stability of ojeok-san by measuring ephedrine concentration of urine after taking ojeok-san [dissertation]. Seoul: KyungHee University;2012.


39. Strano-Rossi S, Leone D, de la Torre X, Botre F. The relevance of the urinary concentration of ephedrines in anti-doping analysis: Determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments. Ther Drug Monit. 2009; Aug. 31:4. 520–6.
crossref pmid

40. Strano-Rossi S, Leone D, de la Torre X, Botre F. Analysis of stimulants in oral fluid and urine by gas chromatography-mass spectrometry II: Pseudophedrine. J Anal Toxicol. 2010; May. 34:4. 210–5.
crossref pmid

41. Barroso O, Goudreault D, Carbo Banus ML, Ayotte C, Mazzoni I, Boghosian T, et al. Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: Implications for doping control analysis of these stimulants banned in sport. Drug Test Anal. 2012; May. 4:5. 320–9.
crossref pmid

42. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol Sci. 2000; Aug. 56:2. 424–30.
crossref pmid

43. Lee NR, Ha HK, Shin HK, Seo CS. Quantification, anti-inflammatory and antioxidant effects of mahwang-tang decoction according to the storage temperature and period. Kor J Pharmacogn. 2018; 49:2. 172–81.


44. Seo CS, Shin HK. Quantitative determination of twelve bioactive components in mahwang-tang, a traditional herbal prescription, using an LC-MS/MS. Yakhak Hoeji. 2016; 60:6. 320–6.
crossref

45. Song MY, Kim HJ, Lee MJ. The safety guidelines for use of ma-huang in obesity treatment. Journal of Korean Oriental Association for Study of Obesity. 2006; 6:2. 17–27.


46. Tyler VE. Herbs of choice: The therapeutic use of phytomedicinals. New York: Pharmaceutical procucts press;1994. p. 88–90.


47. Tong JY, Chao J, Dai YT, Fan ZQ, Wang DD, Qin XM, et al. Establish quality evaluation system for standard ephedrae herba decoction. Zhongguo Zhong Yao Za Zhi. 2017; Mar. 42:5. 823–9.


48. Aghdasi M, Bojnoordi MM, Mianabadi M, Nadaf M. Chemical components of the Ephedra major from Iran. Nat Prod Res. 2016; 30:3. 369–71.
crossref pmid

49. Herbalism textbook compilation committee. Herbalism. 2nd ed. Seoul: Young Lim Press;2011. p. 231–3. p. 289–90. p. 313–4. p. 392–5. p. 645–7. p. 677–8. p. 726


50. Nahas GG. Marijuana in science and medicine. New York: Raven Press;1984. p. 25


51. Bosy TZ, Cole KA. Consumption and quantitation of delta9-tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol. 2000; Oct. 24:7. 562–6.
crossref pmid

52. Cooper ZD, Haney M. Actions of delta-9 -tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. Int Rev Psychiatry. 2009; Apr. 21:2. 104–12.
crossref pmid pmc

53. Katzung BG, Masters SB, Tevor AJ. Basic and clinical pharmacology. 12th ed. Seoul: Panmun;2014. 42:p. 587


54. Ware MA, Jensen D, Barrette A, Vernec A, Derman W. Cannabis and the health and performance of the elite athlete. Clin J Sport Med. 2018; Sep. 28:5. 480–4.
crossref pmid pmc

55. Hilderbrand RL. Hemp & cannabidiol: What is a medicine? Mo Med. 2018; Jul–Aug. 115:4. 306–9.
pmid pmc

56. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009; Nov. 1. 105:1–2. 24–32.
crossref

57. Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 1985; Nov. 38:5. 572–8.
crossref

58. Campos DR, Yonamine M, de Moraes Moreau RL. Marijuana as doping in sports. Sports Med. 2003; 33:6. 395–9.
crossref pmid

59. Brenneisen R, Meyer P, Chtioui H, Saugy M, Kamber M. Plasma and urine profiles of Δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor -9-carboxy-Δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem. 2010; Apr. 396:7. 2493–502.
crossref

60. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol. 2010; May. 34:4. 216–21.
crossref pmid

61. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of Δ9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol. 2007; Jun. 31:5. 288–93.
crossref pmid

62. Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, et al. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl). 2008; Dec. 201:2. 171–81.
crossref pmid

63. Hunault CC, van Eijkeren JC, Mensinga TT, de Vries I, Leenders ME, Meulenbelt J. Disposition of smoked cannabis with high Δ9-tetrahydrocannabinol content: A kinetic model. Toxicol Appl Pharmacol. 2010; Aug. 1. 246:3. 148–53.
crossref pmid

64. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008; Sep. 22:7. 707–16.
crossref pmid

65. Pacifici R, Pichini S, Pellegrini M, Tittarelli R, Pantano F, Mannocchi G, et al. Determination of cannabinoids in oral fluid and urine of “light cannabis” consumers: A pilot study. Clin Chem Lab Med. 2018; Dec. 19. 57:2. 238–43.
crossref pmid

66. Lemberger L, Tamarkin NR, Axelrod J, Kopin IJ. Delta-9-tetrahydrocannabinol: Metabolism and disposition in long-term marihuana smokers. Science. 1971; Jul. 2. 173:3991. 72–4.
crossref pmid

67. General information on herbal medicine [Internet]. Cheongju: National Institute of Food and Drug Safety Evaluation;c2009. Strychni Ignatii Semen; [cited 2018 Nov 18]; [about 1 p.]. Available from: http://nifds.go.kr/herb/m_442/view.do;jsessionid=u45mKSqBUljNUaMuzwQvB29NZjHdkwRgwxelQTMPSAjn5unI0MvSyh0AE3A8jt7c.nifds_was2_servlet_engine1?code=KHP-N136&page=22


68. Gu ZP, Zhang SM, Wang CL, Lian WY, Xiao PG, Chen JM. Determation of strychnine and brucine in strychnos by HPLC. Yao Xue Xue Bao. 1997; Oct. 32:10. 791–4.
pmid

69. Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. Liquid chromatography/ photodiode array detection for determination of strychnine in blood: A fatal case report. Forensic Sci Int. 2004; Apr. 20. 141:1. 17–21.
crossref pmid

70. Emergency Response Safety and Health Database [Internet]. Atlanta: The National Institute for Occupational Safety and Health (NIOSH);[date unknown] - . STRYCHNINE : Biotoxin; [reviewed 2011 May 12 cited 2018 Nov 29]; [about 12 screens]. Available from: https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750018.html


71. Gossel TA, Bricker JD, editors. Principles of clinical toxicology. 3rd ed. New York: Raven Press;1994. p. 351


72. Goodman LS, Gilman AG. Goodman and gilman’s the pharmacological basis of therapeutics. New York: Macmillan Publishing & Co., Inc;1985. p. 582–4.


73. Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J. Ellenhorn’s medical toxicology: Diagnosis and treatment of human poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins;1997. p. 1660


74. Palatnick W, Meatherall R, Sitar D, Tenenbein M. Toxicokinetics of acute strychnine poisoning. J Toxicol Clin Toxicol. 1997; 35:6. 617–20.
crossref pmid

75. Edmunds M, Sheehan TM, Van’t Hoff W. Strychnine poisoning: Clinical and toxicological observations on a non-fatal case. J Toxicol Clin Toxicol. 1986; 24:3. 245–55.
crossref

76. Wood DM, Webster E, Martinez D, Dargan PI, Jones AL. Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. Crit Care. 2002; Oct. 6:5. 456–9.
crossref

77. Gupta RC, Patocka J. Handbook of toxicology of chemical warfare agents. London: Academic Press;2009. p. 199


78. Van Eenoo P, Deventer K, Roels K, Delbeke FT. Quantitative LC–MS determination of strychnine in urine after ingestion of a strychnos nux-vomica preparation and its consequences in doping control. Forensic Sci Int. 2006; Dec. 20. 164:2–3. 159–63.
crossref

79. Li J, Jiang Y. Rapid and sensitive determination of strychnine and brucine in human urine by capillary electrophoresis with field–amplified sample stacking. Biomed Chromatogr. 2010; Feb. 24:2. 186–94.
pmid

80. Kong HY, Zhou W, Guo PH, Sang ZC, Wu GN, Chen YJ, et al. Safety of individual medication of Ma Qian Zi (semen strychni) based upon assessment of therapeutic effects of Guo’s therapy against moderate fluorosis of bone. J Tradit Chin Med. 2011; Dec. 31:4. 297–302.
crossref

81. Xu T, Zhang Y, Yu J. HPLC determination of strychnine in nux vomica powder. Heilongjiang Medicine Journal. 2012; 25:1. 11–2.


82. Tang HB, Zhang LJ, Li XL, Sun CF, Ma PJ. The experimental study of diferent solvent extracting total alkaloid from semen strychni. Guiding Journal of Traditional Chinese Medicine and Pharmacy. 2009; 15:11. 52–3.


83. Hu TG. Impact of traditional chinese medicine processing on physicochemical properties and efficacy of herbs. E–J Transl Med. 2015; 2:4. 115–6.


84. Xu WF, Zhang BG, Li M, Liu GH. Determination of ephedrine in rhizoma pinelliae, rhizoma typhonii flagelliformis and their processed products by HPLC. LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH. 2007; 18:4. 884–5.


85. Qi HH, Wu JL, Xiang LY, Duan GL. Determination of ephedrine hydrochloride and pseudoephedrine hydrochloride in rhizoma pinelliae granules by HPLC. Science and Technology Innovation Herald. 2008; Aug. 12. 16:2(col. 1)


86. Li ZH, Nie J, Ni KY, Du GH. Comparison of raizoma pinelliae from different producing areas. JOURNAL OF ANALYTICAL SCIENCE. 2005; 21:4. 393–5.


87. Zhu JJ, Guo ZY, Zhou Y, Yang J, Wang JZ, Zou K. Determination of alkaloids and the ephedrine in wild and tissue culture pinellia ternata(thunb) breit. Paper presented at: Seminar on the development and protection of Chinese herbal medicine and natural product resources. 2009 Sep 13; China Association for Pharmaceuticals and Medical Devices Technology Exchange(CPDE);Guilin, China:


88. Wu H, Tan X, Cai B, Ye D. Effect of ginger-processing on l-ephedrine contents in rhizoma pinelliae. Zhongguo Zhong Yao Za Zhi. 1996; Mar. 21:3. 157158190


89. Jeong JG. A herbological study on the plants of papaveraceae in Korea. Kor J Herbol. 2016; 31:5. 63–9.
crossref

90. Choe S, Kim S, Lee C, Yang W, Park Y, Choi H, et al. Species identification of Papaver by metabolite profiling. Forensic Sci Int. 2011; Sep. 10. 211:1–3. 51–60.
crossref pmid

91. Sárközi Á, Janicsak G, Kursinszki L, Kery A. Alkaloid composition of Chelidonium majus L. studied by different chromatographic techniques. Chromatographia. 2006; 63:13. S81–6.
crossref

92. State Administration of Traditional Chinese Medicine. Chinese herbal medicine. 3:Beijing: Shanghai Science and Technology Press;1999. p. 616–9.


93. Xinwenfeng Publishing Editorial Department. New chinese medicine dictionary. Taipei: Xinwenfeng Publishing Co., Ltd;1981. p. 605–6.


94. Fu Z, Fan X, Wang X, Gao X. Cistanches herba: An overview of its chemistry, pharmacology, and pharmacokinetics property. J Ethnopharmacol. 2018; Jun. 12. 219:233–47.
crossref

95. Koehler K, Thevis M, Schaenzer W. Meta–analysis: Effects of glycerol administration on plasma volume, haemoglobin, and haematocrit. Drug Test Anal. 2013; Nov–Dec. 5:11–12. 896–9.
crossref

96. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean–Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: An update. Obes Rev. 2006; Feb. 7:1. 79–88.
crossref pmid

97. Stohs SJ, Preuss HG, Shara M. A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects. Oxid Med Cell Longev. 2011; 2011:482973.
crossref pmid pmc

98. Gutiérrez-Hellín J, Salinero JJ, Abían-Vicen J, Areces F, Lara B, Gallo C, et al. Acute consumption of p-synephrine does not enhance performance in sprint athletes. Appl Physiol Nutr Metab. 2016; Jan. 41:1. 63–9.
crossref pmid pmc

99. Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60 day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 2013; May. 55:358–62.
crossref

100. Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012; 9:7. 527–38.
crossref pmid pmc

101. Medana C, Calza P, Giancotti V, Dal Bello F, Aragno M, Baiocchi C. Study of the photocatalytic transformation of synephrine: A biogenic amine relevant in anti-doping analysis. Anal Bioanal Chem. 2013; Jan. 405:2–3. 1105–13.
crossref pmid

102. Shara M, Stohs SJ, Smadi MM. Safety evaluation of p–synephrine following 15 days of oral administration to healthy subjects: A clinical study. Phytother Res. 2018; Jan. 32:1. 125–31.
crossref

103. Ke X, Liu J, Chen C. HPLC fa ce ding cang zuo pen bi ye ji zuo shi yao cai zhong xin fu lin de han liang. Traditional Chinese Drug Research and Clinical Pharmacology. 2003; 14:1. 45–6.


104. Luo Z, Jing H. Content determination of synephrine in citrus auarntium L. by reversed phase ion-pair HPLC. China Pharmacy. 2006; 17:19. 1502–3.


105. Lu XF, Wang RJ, Peng GP, Deng YT. Determination of the content of synephrine in fructus aurantii immaturus by packed-column supercritical fluid chromatography. Liaoning Journal of Traditional Chinese Medicine. 2006; 33:2. 222–3.


106. Zhao Y, Xie PS, Lu PH, Wang XH, Yang H. Determination of synephrine in Fructus aurantii immatus, Fructus aurantii, Pericarpium citri reticulatae viride and Pericarpium citri reticulatae. World Science and Technology/ Modernization of Traditional Chinese Medicine and Materia Medica. 2006; 8:4. 6467106


107. Nelson BC, Putzbach K, Sharpless KE, Sander LC. Mass spectrometric determination of the predominant adrenergic protoalkaloids in bitter orange (Citrus aurantium). J Agric Food Chem. 2007; Nov. 28. 55:24. 9769–75.
crossref pmid

108. Shawky E. Determination of synephrine and octopamine in bitter orange peel by HPTLC with densitometry. J Chromatogr Sci. 2014; Sep. 52:8. 899–904.
crossref pmid

109. Tanaka S, Sekiguchi M, Yamamoto A, Aizawa S, Sato K, Taga A, et al. Separation of synephrine enantiomers in citrus fruits by a reversed phase HPLC after chiral precolumn derivatization. Anal Sci [Internet]. 2018. Dec. 14. [cited 2018 Dec 15]:[about 27 p.]. Available from: https://doi.org/10.2116/analsci.18P441 10.2116/analsci.18P44130555107.
crossref pmid

110. Wang J, He Y, Liu X, Yang Z, Yang W. Steroid profile and IRMS analysis of musk administration for doping control. Drug Test Anal. 2017; Nov. 9:11–12. 1779–87.
crossref pmid

111. Thevis M, Schanzer W, Geyer H, Thieme D, Grosse J, Rautenberg C, et al. Traditional Chinese medicine and sports drug testing: Identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. Br J Sports Med. 2013; Jan. 47:2. 109–14.
crossref pmid

112. He Y, Wang J, Liu X, Xu Y, He Z. Influences of musk administration on the doping test. Steroids. 2013; Nov. 78:11. 1047–52.
crossref pmid

113. Zhang HL. Extracts from plastrum testudinis (PTD) promote proliferation of rat mesenchymal stem cell(MSCs) through BMP/ID pathway [dissertation]. Guangzhou: Guangzhou university of chinese medicine;2009.


114. State Administration of Traditional Chinese Medicine. Chinese herbal medicine. 9:Beijing: Shanghai Science and Technology Press;1999. p. 536–40. p. 593–5.


115. Granados J, Gillum TL, Christmas KM, Kuennen MR. Prohormone supplement 3b-hydroxy-5a-androst-1-en-17-one enhances resistance training gains but impairs user health. J Appl Physiol (1985). 2014; Mar. 1. 116:5. 560–9.
crossref

116. SLAUNWHITE WR, SANDBERG AA. Metabolism of 4-C14–testosterone in human subjects III. Fate of androsterone and etiocholanolone. J Clin Endocrinol Metab. 1958; Oct. 18:10. 1056–66.
crossref pmid

117. Institute of pharmacopuncturology. Pharmacopuncturology. Seoul: Elsevier Korea L.L.C;2008. p. 200–7.
pmid pmc

118. Lee SK, Lee JD, Koh HK. The study on the Hominis Placenta aqua-acupuncture solution. The Journal of Korea Acupuncture & Moxibustion Society. 2000; 17:1. 67–74.


119. NECA [Internet]. Seoul: NECA;c2017. Evaluation of medical technology regarding clinical effectiveness and safety of human placenta injection. 2010. Jul. 19. [cited 2018 Nov 24]; [about 203 p.]. Available from: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=22


120. Melsmon [Internet]. Tokyo: Millennia Concepts (Official Website);c2015. [cited 2018 Nov 29]. Available from: http://melsmon.com/


121. Tsukiyama M, Ueki T, Yasuda Y, Kikuchi H, Akaishi T, Okumura H, et al. B2-adrenoceptor -mediated tracheal relaxation induced by higenamine from Nandina domestica . Thunberg Planta Med. 2009; Oct. 75:13. 1393–9.
crossref pmid

122. Kashiwada Y, Aoshima A, Ikeshiro Y, Chen YP, Furukawa H, Itoigawa M, et al. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure–activity correlations with related alkaloids. Bioorg Med Chem. 2005; Jan. 17. 13:2. 443–8.
crossref pmid

123. Chang YC, Chang FR, Khalil AT, Hsieh PW, Wu YC. Cytotoxic benzophenanthridine and benzylisoquinoline alkaloids from Argemone mexicana . Z Naturforsch C. 2003; Jul–Aug. 58:7–8. 521–6.
crossref pmid

124. Kimura I, Chui LH, Fujitani K, Kikuchi T, Kimura M. Inotropic effects of (±)-higenamine and its chemically related components, ( )-R- coclaurine and ( )-S-reticuline, contained in the traditional sino-japanese medicines “Bushi” and “Shin-i” in isolated guinea pig papillary muscle. Jpn J Pharmacol. 1989; May. 50:1. 75–8.
crossref pmid

125. Bai G, Yang Y, Shi Q, Liu Z, Zhang Q, Zhu YY. Identification of higenamine in Radix Aconiti Lateralis Preparata as a beta2 -adrenergic receptor agonist. Acta Pharmacol Sin. 2008; Oct. 29:10. 1187–94.
crossref pmid

126. Kang YJ, Lee YS, Lee GW, Lee DH, Ryu JC, Yun-Choi HS, et al. Inhibition of activation of nuclear factor kappaB is responsible for inhibition of inducible nitric oxide synthase expression by higenamine, an active component of aconite root. J Pharmacol Exp Ther. 1999; Oct. 291:1. 314–20.
pmid

127. Praman S, Mulvany MJ, Williams DE, Andersen RJ, Jansakul C. Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats. J Ethnopharmacol. 2012; Mar. 6. 140:1. 166–78.
crossref pmid

128. Minami H, Dubouzet E, Iwasa K, Sato F. Functional analysis of norcoclaurine synthase in Coptis japonica . J Biol Chem. 2007; Mar. 2. 282:9. 6274–82.
crossref pmid

129. Zhang N, Lian Z, Peng X, Li Z, Zhu H. Applications of higenamine in pharmacology and medicine. J Ethnopharmacol. 2017; Jan. 20. 196:242–52.
crossref pmid

130. Lee SR, Schriefer JM, Gunnels TA, Harvey IC, Bloomer RJ. Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acids and energy expenditure in human subjects. Lipids Health Dis. 2013; Oct. 21. 12:148
crossref pmid pmc

131. Feng S, Jiang J, Hu P, Zhang JY, Liu T, Zhao Q, et al. A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy chinese subjects. Acta Pharmacol Sin. 2012; Nov. 33:11. 1353–8.
crossref pmid pmc

132. Okano M, Sato M, Kageyama S. Determination of higenamine and coclaurine levels in human urine after the administration of a throat lozenge containing Nandina domestica fruit. Drug Test Anal. 2017; Nov. 9:11–12. 1788–93.
crossref

133. Du YR, Li F, Xu RY, Zhang Y, Ouyang M, Jing HL. Tolerability of higenamine hydrochloride in healthy volunteers. Chin J Clin Pharmacol. 2007; 23:4. 125–60.


134. Tian HF. Determination of higenamine by reversed phase high performance liquid chromatography with precolumn derivatization [dissertation]. Yanji city: Yanbian university;2011.


135. Tian HF, Yi T, Jing DR. Determination of higenamine in Nelumbo nucifera by HPLC with precolumn derivatization. Journal of Yanbian University(Natural Sciene). 2012; 38:2. 150–3.


136. Yang M, He S, Zhang D, Sun B, Wang Y. Study on determination of higenamine in chinese medicinal materials by LC-MS/MS. China measurement & test. 2018; 44:3. 61–5.


137. Kim SY, Geum DH, Lee MJ. A study on doping test of Bojungchisheup-tang . Korean J Ori Med. 1997; 3:1. 289–319.


138. Yoo HJ. Verification of efficacy as an ergogenic aid and safety in doping of Sibjeondaebo-tang [dissertation]. Seoul: Kyunghee university;2014.
pmid pmc

139. Lee JH. SK lim seok jin detection of doping...36 games ‘suspension’. The Kyunghyang Shinmun. 2017; Oct. 28. Sect A:24(col. 6)


140. Kim HJ, Kwak BM, Ahn JH, Park JS. Simultaneous determination of synephrine and N-methyltyramine in orange fruit and juice from korean market by UPLC-FLD. Korean J Food Sci Technol. 2014; 46:3. 276–82.
crossref

141. Balasubramanian J, Maraicar KSH, Ananth DB, Vijayakumar N, Dhanalakishmi R. DHEA: The remedy for andropause. Indian J Med Healthcare. 2012; May. 1:2. 25–31.


142. Son YI. Verification and verification, seeking 100% safety : The placenta, which has been processed for 11 weeks at the greencross placenta injection plant in chungbuk eumseong, has been turned into a medicine. Weekly Donga. 2009; Oct. 27. 708:36–9.


Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953@daum.net
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI